Sotyktu

Sotyktu (deucravacitinib) is used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is a Tyrosine Kinase 2 (TYK2) Inhibitor, which works by binding to the tyrosine kinase 2 protein and preventing the activation of a downstream inflammatory response. Sotyktu is available as a 6mg tablet. There are currently no generic alternatives for Sotyktu. It is covered by some Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower.

With the Patient Assistance Program from Bristol Myers Squibb, receive your prescription at no cost if you are eligible.